Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1981 1
1983 2
1985 2
1986 5
1987 2
1988 7
1989 5
1990 6
1991 3
1992 4
1993 2
1994 6
1995 5
1996 5
1997 5
1998 4
1999 2
2000 7
2001 4
2002 1
2004 4
2006 1
2007 1
2011 1
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic applications of ribozymes.
Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Kijima H, et al. Among authors: scanlon kj. Pharmacol Ther. 1995;68(2):247-67. doi: 10.1016/0163-7258(95)02008-x. Pharmacol Ther. 1995. PMID: 8719970 Review.
Cisplatin resistance in human cancers.
Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Scanlon KJ, et al. Pharmacol Ther. 1991 Dec;52(3):385-406. doi: 10.1016/0163-7258(91)90033-i. Pharmacol Ther. 1991. PMID: 1820582 Review.
The promised land.
Sobol RE, Scanlon KJ. Sobol RE, et al. Among authors: scanlon kj. Cancer Gene Ther. 2013 Dec;20(12):651. doi: 10.1038/cgt.2013.73. Cancer Gene Ther. 2013. PMID: 24346318 No abstract available.
Oligonucleotides as modulators of cancer gene expression.
Curcio LD, Bouffard DY, Scanlon KJ. Curcio LD, et al. Among authors: scanlon kj. Pharmacol Ther. 1997;74(3):317-32. doi: 10.1016/s0163-7258(97)00005-3. Pharmacol Ther. 1997. PMID: 9352587 Review.
Ribozyme-mediated cancer gene therapy.
Irie A, Bouffard DY, Scanlon KJ. Irie A, et al. Among authors: scanlon kj. Int J Urol. 1997 Jul;4(4):329-37. doi: 10.1111/j.1442-2042.1997.tb00203.x. Int J Urol. 1997. PMID: 9256319 Free article. Review. No abstract available.
Anti-oncogene ribozymes for cancer gene therapy.
Irie A, Kijima H, Ohkawa T, Bouffard DY, Suzuki T, Curcio LD, Holm PS, Sassani A, Scanlon KJ. Irie A, et al. Among authors: scanlon kj. Adv Pharmacol. 1997;40:207-57. doi: 10.1016/s1054-3589(08)60141-6. Adv Pharmacol. 1997. PMID: 9217927 Review. No abstract available.
Anti-genes: siRNA, ribozymes and antisense.
Scanlon KJ. Scanlon KJ. Curr Pharm Biotechnol. 2004 Oct;5(5):415-20. doi: 10.2174/1389201043376689. Curr Pharm Biotechnol. 2004. PMID: 15544489 Review.
Commercializing medical technology.
Scanlon KJ, Lieberman MA. Scanlon KJ, et al. Cytotechnology. 2007 Apr;53(1-3):107-12. doi: 10.1007/s10616-007-9056-5. Epub 2007 Feb 28. Cytotechnology. 2007. PMID: 19003196 Free PMC article.
89 results